Cardiovascular risk associated with high sodium-containing drugs: A systematic review

• Published in: PloS one 2017-07, Vol.12 (7), p.e0180634-e0180634
• Main Authors: Perrin, Germain, Korb-Savoldelli, Virginie, Karras, Alexandre, Danchin, Nicolas, Durieux, Pierre, Sabatier, Brigitte
• Format: Article
• Language: English
• Subjects: Analgesics; Blood pressure; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - chemically induced; Comorbidity; Complications; Diabetes mellitus; Dialysis; Diet; Drug dosages; Drug therapy; Drugs; Exposure; Fluctuations; Health risks; Heart failure; Hospitals; Humans; Hypertension; Incidence; Information science; Life Sciences; Medicine and Health Sciences; Nonsteroidal anti-inflammatory drugs; Nutrition; Parameter modification; Parenteral nutrition; Patients; Pharmaceutical Preparations - chemistry; Pharmaceuticals; Pharmacy; Physical Sciences; Populations; Precision medicine; Prospero protein; Quality assessment; Research and Analysis Methods; Risk analysis; Risk factors; Salt; Santé publique et épidémiologie; Sodium; Sodium - administration & dosage; Sodium - adverse effects; Studies; Tablets; Water pollution effects
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0180634

Excess dietary sodium is associated with increased blood pressure (BP). Some drugs are associated with high sodium intake (in particular effervescent tablets), but the cardiovascular risk associated with such high sodium-containing drugs (HSCD) is largely underevaluated. To summarize the evidence for a potential cardiovascular risk associated with exposure to HSCD, and to highlight possible risk factors associated with this iatrogenic issue; in general and/or specific populations. We conducted a systematic review, by searching electronic databases including MEDLINE, EMBASE, Web of Science, CENTRAL and grey literature between 1960 and 2015. We included studies that reported modification of cardiovascular parameters or incidence/prevalence of cardiovascular outcomes, between a group of subjects exposed to HSCD relative to a non-exposed group. The threshold used to identify HSCD was 391 mg/day. We did not consider studies evaluating exposure to sodium as an active ingredient or those focusing on dialysis solutions or enteral/parenteral nutrition. Study quality was assessed using the EPHPP tool. A total of eight studies met our inclusion criteria. Four reported results for short-term exposure to HSCD (≤ 7 days) on BP fluctuations. One study reported an elevation of BP (associated sodium intake: 1,656 mg/day). Four studies evaluated a long-term exposure (≥ 2 years or discontinuation of a chronic treatment). Two studies reported iatrogenic risk. For these studies, drug associated sodium intake was high (> 1,500 mg/day) in patients with comorbidities (in particular, diabetes mellitus and hypertension). Despite numerous study limitations, this systematic review suggests three potential synergistic risk factors for cardiovascular complications after exposure to HSCD: a high sodium intake (≥ 1,500 mg/day), a long duration of exposure, and the presence of comorbidities. Further studies are required to characterize this iatrogenic risk. PROSPERO CRD42016047086.